Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. META
5. MU
6. NVDA
7. BLZE
8. IBM
9. PRIM
10. ACN

Go back to Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor

Praxis Precision Medicines Inc. (PRAX) PT Raised to $500 at Truist Securities

December 8, 2025 6:26 AM EST

Truist Securities analyst Joon Lee raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $500.00 (from $360.00) while maintaining a Buy rating.

The analyst comments "Vormatrigine reported 100% median seizure reduction at week 8, which was sustained through wk 16 in full Ph2 RADIANT. The results... More